1. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP (2010) Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 363(20):1889–1899.
https://doi.org/10.1056/NEJMoa1002625
2. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377(9763):393–402.
https://doi.org/10.1016/S0140-6736(10)60959-2
3. Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, Parikh AR, Broder K, Calvo KR, Wu CO, Young NS, Dunbar CE (2014) Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood 123(12):1818–1825.
https://doi.org/10.1182/blood-2013-10-534743
4. Afdhal N, Duggal A, Ochiai T, Motomiya T, Kano T, Nagata T, Peck-Radosavlejic M (2017) Platelet response to lusutrombopag, a thrombopoietin receptor agonist, in patients with chronic liver disease and thrombocytopenia undergoing non-emergency invasive procedures: results form a phase 3 randomized, double-blind, placebo-controlled study. Blood 130:291 (Abstract)
5. Terrault N, Kuter DJ, Isumi N, Kayali Z, Mitrut P, Tak WY, Bibbiani F (2017) Superiority of avatrombopag to placebo in increasing platelet counts in patients with chronic liver disease-associated thrombocytopenia undergoing scheduled procedures: results from 2, phase 3 randomized studies. Blood 130:18 (Abstract)